Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis

Table 2

Effect of azilsartan (Azil) and placebo on ESR and hs-CRP levels and the clinical evaluation scores of patients with active RA maintained on methotrexate (MTX).

Clinical Score	MTX + placebo,		MTX + Azil,
	Baseline	After 90 days	Baseline	After 90 days
DAS-28
SDAI
HAQ-DI
CDAI
TJC-28
SJC-28
Pain VAS-100 (mm)
EGA (cm)
Morning stiffness (min)
ESR (mm/hr)
hsCRP (μg/ml)

Values are presented as mean ± SD; = number of patients; different compared to pretreatment within the same group ; values with different superscripts (a, b) among groups are significantly different . RA: rheumatoid arthritis; TJC: tender joint count; SJC: swollen joint count; VAS: visual analogue scale; EGA: evaluator global assessment; ESR: erythrocyte sedimentation rate; hsCRP: highly sensitive C-reactive protein; DAS-28: 28-joint disease activity score; SDAI: simple disease activity index; HAQ-DI: health assessment questionnaire disability index; CDAI: clinical disease activity index.